Rad52 inactivation is synthetically lethal with BRCA2 deficiency

Zhihui Feng, Shaun P. Scott, Wendy Bussen, Girdhar G. Sharma, Gongshe Guo, Tej K. Pandita, Simon N. Powell

Research output: Contribution to journalArticlepeer-review

270 Scopus citations


Synthetic lethality is a powerful approach to study selective cell killing based on genotype. We show that loss of Rad52 function is synthetically lethal with breast cancer 2, early onset (BRCA2) deficiency, whereas there was no impact on cell growth and viability in BRCA2-complemented cells. The frequency of both spontaneous and double-strand break-induced homologous recombination and ionizing radiation-induced Rad51 foci decreased by 2-10 times when Rad52 was depleted in BRCA2-deficient cells, with little to no effect in BRCA2-complemented cells. The absence of both Rad52 and BRCA2 resulted in extensive chromosome aberrations, especially chromatid-type aberrations. Ionizing radiation-induced and S phase-associated Rad52-Rad51 foci form equally well in the presence or absence of BRCA2, indicating that Rad52 can respond to DNA double-strand breaks and replication stalling independently of BRCA2. Rad52 thus is an independent and alternative repair pathway of homologous recombination and a target for therapy in BRCA2-deficient cells.

Original languageEnglish (US)
Pages (from-to)686-691
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Issue number2
StatePublished - Jan 11 2011


  • Chromosomal aberrations
  • DNA repair
  • Genetic instability

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Rad52 inactivation is synthetically lethal with BRCA2 deficiency'. Together they form a unique fingerprint.

Cite this